Engineered Lactobacillus paracasei Producing Palmitoylethanolamide (PEA) Prevents Colitis in Mice
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- Mice in a model of ulcerative colitis
- Dose used in the study
- An engineered Lactobacillus paracasei F19 expressing NAPE-PLD, given with ultra-low palmitate so that the bacteria produce palmitoylethanolamide in the gut; doses not stated
- Duration
- Not stated in the abstract
- What was measured
- Time course of PEA release; clinical and histological damage scores; neutrophil infiltration; cytokines; oxidative stress markers; epithelial barrier integrity.
What the authors reported
Co-administration of the engineered bacteria and palmitate released PEA over time and reduced clinical and histological damage, neutrophil infiltration, pro-inflammatory cytokines and oxidative stress markers, with improved epithelial barrier integrity. No numbers are given in the abstract.
Limits of this study
A mouse model using a genetically engineered probiotic, not a PEA supplement; it cannot show effect in people. Numbers are not given in the abstract. The authors declare no conflict of interest.
Source
PubMed 33799405 · doi:10.3390/ijms22062945
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.